- Regulatory Status
- RUO
- Other Names
- IL-1F3, IL-1RA, ICIL-1RA, IRAP, IL-1RN, DIRA
-
D10.G4.1 cell proliferation induced by IL-1α in the presence of IL-1RA.
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 553902 | 10 µg | $59.00 | |||
| 553904 | 25 µg | $112.00 | |||
| 553906 | 100 µg | $223.00 | |||
| 553908 | 500 µg | $762.00 | |||
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
IL-1 receptor antagonist, IL-1RA, was initially purified from medium conditioned by human monocytes. IL-1RA belongs to the IL-1 family, which includes 11 members: IL-1α, IL-1β, IL-18, IL-33, and IL-F5 to IL-1F10. Although all members are secreted proteins, IL-RA is the only one that possesses a signal peptide, and it is secreted via the endoplasmic reticulum and Golgi apparatus. In addition to the glycosylated secreted IL-1RA, an intracellular unglycosylated isoform has been described. The two forms of IL-1RA are encoded by a single gene, generated by alternative usage of the first two exons, and their expression is regulated by two promoters. IL-1RA binds tightly to IL-1R1, blocks the binding of IL-1α and IL-1β to the receptor, inhibits the recruitment of IL-1RAP (a receptor accessory protein), and thus the signal transduction induced by IL-1α and IL-1β. IL-1RA also binds to the non-signaling/decoy receptor IL-1RII. IL-1RA exhibits potent anti-inflammatory properties in vivo and can mediate protective effects against inflammatory diseases. IL-1RA has been used in controlled clinical trials for the treatment of rheumatoid arthritis (RA). It has been reported that it reduces clinical signs and symptoms associated with the disease. IL-1RA (Kineret®, Anakinra) has also been used in the treatment of type 2 diabetes and RA.
Product Details
- Source
- Human IL-1RA, amino acids Met-(Arg8-Glu159) (Accession# NM_000577), was expressed in E. coli.
- Molecular Mass
- The 153 amino acid recombinant protein has a predicted molecular mass of approximately 17.2 kD. The DTT-reduced and non-reduced glycosylated protein migrate at approximately 17 kD and 18 kD, respectively, by SDS-PAGE. The predicted N-terminal amino acid is Met.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS, pH 7.2.
- Endotoxin Level
- Less than 0.01 ng per µg cytokine as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- ED50 = 7 - 35 ng/ml, corresponding to a specific activity of 0.2 - 1.4 x 105 units/mg, as determined by inhibition of D10.G4.1 cell proliferation induced by human IL-1α.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
- Product Citations
-
Antigen Details
- Structure
- Receptor
- Distribution
- Monocytes, neutrophils, macrophages, endothelial cells, corneal epithelial cells, oral mucosa epithelial cells, and fibroblasts.
- Function
- Inhibits the activity of IL-1β and IL-1α by binding to receptor IL1R1 and blocking the downstream signaling.IL-1RA is induced by IL-1, LPS, IgG complexes, IL-4, and IL-10.
- Ligand/Receptor
- Type I and II IL-1 receptors (IL-1RI and IL-1RII).
- Bioactivity
- Inhibition of D10.G4.1 cell proliferation.
- Cell Type
- Hematopoietic stem and progenitors
- Biology Area
- Stem Cells
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
1. Hannun CH, et al. 1990. Nature 343:336.
2. Cohen S, et al. 2002. Arthritis Rheum. 46:614.
3. Arend WP, et al. 2002. Cytokine Growth Factor Rev. 13:323.
4. Botsios C, et al. 2007. Reumatismo 59:32.
5. Larsen C, et al. 2007. N Engl J Med. 356:1517. - Gene ID
- 3557 View all products for this Gene ID
- UniProt
- View information about IL-1RA on UniProt.org